MétaCan
Menu
Back to cohort
Record W1893794029 · doi:10.1177/1352458515594041

The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis

2015· article· en· W1893794029 on OpenAlexafffund
Matthew Warrender‐Sparkes, Tim Spelman, Guillermo Izquierdo, María Trojano, Alessandra Lugaresi, François Grand’Maison, Eva Havrdová, Dana Horáková, Cavit Boz, Celia Oreja‐Guevara, Raed Alroughani, Gerardo Iuliano, Pierre Duquette, Marc Girard, Murat Terzi, Raymond Hupperts, Pierre Grammond, Thor Petersen, Ricardo Fernández‐Bolaños, Marcela Fiol, Eugenio Pucci, Jeannette Lechner‐Scott, Freek Verheul, Edgardo Cristiano, Vincent Van Pesch, Tatjana Petkovska‐Boskova, Fraser Moore, Ilya Kister, Roberto Bergamaschi, María Laura Saladino, Mark Slee, Michael Barnett, Maria Pia Amato, Cameron Shaw, Neil Shuey, Carolyn Young, Orla Gray, Ludwig Kappos, Helmut Butzkueven, Tomáš Kalinčík, Vilija Jokubaitis

Bibliographic record

VenueMultiple Sclerosis Journal · 2015
Typearticle
Languageen
FieldMedicine
TopicMultiple Sclerosis Research Studies
Canadian institutionsJewish General HospitalCégep de LévisHôpital Notre-DameHôpital Charles-Le Moyne
FundersNational Health and Medical Research CouncilCanadian Institutes of Health ResearchNovartis PharmaEMD SeronoH. Lundbeck A/SEli Lilly and CompanyCSL BehringBiogenAssociazione Italiana Sclerosi MultiplaSanofiEuropean CommissionPfizerMultiple Sclerosis AustraliaTeva Pharmaceutical IndustriesNational Research Foundation
KeywordsMultiple sclerosisPersistence (discontinuity)MedicineImmunology

Abstract

fetched live from OpenAlex

OBJECTIVE: We aimed to analyse the effect of the introduction of fingolimod, the first oral disease-modifying therapy, on treatment utilisation and persistence in an international cohort of patients with multiple sclerosis (MS). METHODS: MSBASIS, a prospective, observational sub-study of the MSBase registry, collects demographic, clinical and paraclinical data on patients followed from MS onset (n=4718). We conducted a multivariable conditional risk set survival analysis to identify predictors of treatment discontinuation, and to assess if the introduction of fingolimod has altered treatment persistence. RESULTS: A total of 2640 patients commenced immunomodulatory therapy. Following the introduction of fingolimod, patients were more likely to discontinue all other treatments (hazard ratio 1.64, p<0.001) while more patients switched to fingolimod than any other therapy (42.3% of switches). Patients switched to fingolimod due to convenience. Patients treated with fingolimod were less likely to discontinue treatment compared with other therapies (p<0.001). Female sex, country of residence, younger age, a high Expanded Disability Status Scale score and relapse activity were all independently associated with higher rates of treatment discontinuation. CONCLUSION: Following the availability of fingolimod, patients were more likely to discontinue injectable treatments. Those who switched to fingolimod were more likely to do so for convenience. Persistence was improved on fingolimod compared to other medications.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.002
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.323
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0020.002
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0010.001
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.227
GPT teacher head0.318
Teacher spread0.091 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations35
Published2015
Admission routes2
Has abstractyes

Explore more

Same venueMultiple Sclerosis JournalSame topicMultiple Sclerosis Research StudiesFrench-language works237,207